BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-13@catalystbrief.girapphe.com
DTSTAMP:20261117T061545Z
LAST-MODIFIED:20261117T061545Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. — AK10
 5 Injection [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Phase III Clinical Trial of AK105
  Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib
  in Subjects With Advanced Hepatocellular Carcinoma (HCC).\nSource: https:
 //clinicaltrials.gov/study/NCT04344158\nhttps://catalystbrief.girapphe.com
 /e/13?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/13?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
